Workflow
Doximity(DOCS)
icon
Search documents
Tempus AI vs. Doximity: Which AI in Healthcare Stock is a Better Buy?
ZACKS· 2025-04-11 20:00
Artificial intelligence (AI) is rapidly being integrated into every domain of healthcare, giving birth to a new class of tech-driven innovators. Tempus AI (TEM) and Doximity (DOCS) stand out as emerging players in the AI health tech space. These two offer distinct approaches to innovation and market disruption.Tempus AI is focused on leveraging AI-driven precision medicine, particularly in oncology and chronic disease management, while Doximity operates as a digital platform connecting medical professionals ...
Doximity (DOCS) Falls More Steeply Than Broader Market: What Investors Need to Know
ZACKS· 2025-03-27 23:20
In the latest trading session, Doximity (DOCS) closed at $60.55, marking a -1.51% move from the previous day. The stock's change was less than the S&P 500's daily loss of 0.33%. On the other hand, the Dow registered a loss of 0.37%, and the technology-centric Nasdaq decreased by 0.53%.The medical social networking site's stock has dropped by 15.67% in the past month, falling short of the Medical sector's loss of 3.24% and the S&P 500's loss of 4.03%.Investors will be eagerly watching for the performance of ...
Doximity (DOCS) Beats Stock Market Upswing: What Investors Need to Know
ZACKS· 2025-03-21 23:20
Company Performance - Doximity (DOCS) closed at $62.99, with a +0.35% change from the previous day's closing price, outperforming the S&P 500 which gained 0.08% [1] - Over the past month, Doximity's shares have decreased by 16.31%, while the Medical sector and S&P 500 have lost 1.03% and 7.33% respectively [1] Upcoming Earnings - Analysts expect Doximity to report an EPS of $0.27, reflecting an 8% increase year-over-year, with projected revenue of $133.76 million, up 13.3% from the same quarter last year [2] - For the annual period, earnings are anticipated to be $1.31 per share and revenue at $562.98 million, indicating increases of +37.89% and +18.42% respectively from the previous year [3] Analyst Sentiment - Recent revisions in analyst estimates suggest optimism regarding Doximity's business and profitability, with a 1.52% increase in the Zacks Consensus EPS estimate over the last 30 days [3][5] - Doximity currently holds a Zacks Rank of 1 (Strong Buy), which has historically provided an average annual return of +25% since 1988 [5] Valuation Metrics - Doximity's Forward P/E ratio stands at 47.99, significantly higher than the industry's Forward P/E of 16.32, indicating a premium valuation [6] - The company's PEG ratio is currently 2.6, compared to the average PEG ratio of 1.43 for Medical Services stocks [6] Industry Context - The Medical Services industry, part of the broader Medical sector, holds a Zacks Industry Rank of 75, placing it in the top 30% of over 250 industries [7] - Research indicates that industries in the top 50% outperform those in the bottom half by a factor of 2 to 1 [7]
Buy These 5 Top-Ranked Stocks to Play Likely Earnings Beat
ZACKS· 2025-03-12 13:25
It is not surprising that before an earnings season, every investor looks for stocks that can beat market expectations. This is because investors always try to position themselves ahead of time and look to tap stocks that are high-quality in nature.In this regard, we ran a screener that yielded Doximity (DOCS) , Life Time Group Holdings (LTH) , Adtalem Global Education (ATGE) , BioMarin Pharmaceutical (BMRN) and Iridium Communications (IRDM) as the likely winners on the earnings beat potential.Why Is a Posi ...
Buy 5 High-Flying Health & Fitness Stocks Year to Date With More Upside
ZACKS· 2025-03-07 14:50
U.S. stock markets have been suffering from severe volatility since last month. Volatility is likely to remain in the near term primarily due to tariff and trade-related policies taken by the Trump administration. Recently released several key economic data have also shown that the U.S. economy is softening. At present, the broad-market index — the S&P 500 — and the tech-heavy Nasdaq Composite are in negative territory year to date. The blue-chip Dow is trading almost flat. At this juncture, with a pleasant ...
Is Doximity (DOCS) a Solid Growth Stock? 3 Reasons to Think "Yes"
ZACKS· 2025-02-28 18:50
Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying stocks that can fulfill their growth potential is challenging due to associated risks and volatility [1] Group 1: Company Overview - Doximity (DOCS) is highlighted as a recommended growth stock with a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 17.5%, with projected EPS growth of 36% this year, significantly surpassing the industry average of 11% [4] - Doximity's year-over-year cash flow growth is 23.5%, compared to an industry average of -11.2% [5] - The company's annualized cash flow growth rate over the past 3-5 years is 66.7%, while the industry average is 13.4% [6] Group 2: Earnings and Estimates - Positive trends in earnings estimate revisions are crucial, with Doximity experiencing a 15.9% increase in current-year earnings estimates over the past month [8] - The combination of strong earnings growth, cash flow growth, and positive earnings estimate revisions has positioned Doximity as a Zacks Rank 1 stock and earned it a Growth Score of B [10]
Doximity: Rating Downgrade As Near-Term Upside Is Priced In
Seeking Alpha· 2025-02-14 22:53
Core Viewpoint - Doximity (NYSE: DOCS) is considered an attractive investment opportunity due to its potential for organic growth exceeding GDP growth over the next 5-10 years, sustainable competitive advantages, and fair valuation [1] Group 1: Investment Thesis - The company is positioned in a sector expected to experience structural growth [1] - Doximity's profits are derived from sustainable competitive advantages that lead to attractive unit economics [1] - The management is characterized as competent, ethical, and long-term focused [1]
Doximity Momentum, Big Money Support Stays Strong
FX Empire· 2025-02-14 12:49
Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting competent advisors before making any financial decisions, particularly in the context of investments and trading [1]. Group 1 - The website provides general news, personal analysis, and third-party content intended for educational and research purposes [1]. - It explicitly states that the information does not constitute any recommendation or advice for investment actions [1]. - Users are advised to perform their own research and consider their financial situation before making decisions [1]. Group 2 - The website includes information about complex financial instruments such as cryptocurrencies and contracts for difference (CFDs), which carry a high risk of losing money [1]. - It encourages users to understand how these instruments work and the associated risks before investing [1].
Doximity (DOCS) is an Incredible Growth Stock: 3 Reasons Why
ZACKS· 2025-02-12 18:46
Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, the task of finding cutting-edge growth stocks is made easy with the help of the Z ...
Why Doximity (DOCS) Might be Well Poised for a Surge
ZACKS· 2025-02-12 18:20
Doximity (DOCS) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this medical social networking site, should get reflected in its stock price. After all, empirical research shows a strong correlati ...